Market Cap
$378.7M
DR
DRTSW
Alpha Tau Medical Ltd.
—
Market cap$378.7M
High Impact Filing (7/10) Healthcare & Medical Devices
Snapshot
The big-picture read on DRTSW right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
SEC Reports
14
Price chart 30d +1.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 10, 2026 earnings
Jun 3, 2026 SEC Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Medical Ltd. announced a strategic collaboration with Tolmar International Ltd. to develop and commercialize A
6-K — Impact 7/10
Alpha Tau announced positive overall survival results from pooled Phase I/II Alpha DaRT pancreatic cancer studies at ASC
6-K — Impact 7/10
Alpha Tau reported Q1 2026 financial results with net loss widening to $22.9M ($0.26/share) from $8.7M ($0.12/share) YoY
6-K — Impact 5/10
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 9 bullish, 0 bearish, 0 mixed, 5 neutral · avg impact 5.5/10.
BULLISH6-K7/10
Alpha Tau Medical Ltd. announced a strategic collaboration with Tolmar International Ltd. to develop
Jun 3, 2026
BULLISH6-K7/10
Alpha Tau announced positive overall survival results from pooled Phase I/II Alpha DaRT pancreatic c
Jun 1, 2026
NEUTRAL6-K5/10
Alpha Tau reported Q1 2026 financial results with net loss widening to $22.9M ($0.26/share) from $8.
May 18, 2026
BULLISH6-K7/10
Alpha Tau presented interim data from its REGAIN trial of Alpha DaRT for recurrent glioblastoma (GBM
May 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 10, 2026
earnings
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Jul 21, 2026
other
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
Alpha Tau Reports Positive Data Demonstrating 100% ORR and 18.2-Month Median OS with Alpha DaRT® in Combination with Pembrolizumab for HNSCC
Jun 23, 2026
other
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah Medical Center in Israel
Jun 11, 2026
fda
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Trial and Add Two U.S. Sites; Early Interim Results Showed 100% Local Disease Contro
Jun 3, 2026
contract
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for DRTSW.
Shares short
4,004
Settlement Sep 15, 2026
Change vs prior
-24.6%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.0%
Estimate — not % of float
All DRTSW filing & press-release reports (14)
- 6-K reportJun 3, 2026
- 6-K reportJun 1, 2026
- 6-K reportMay 18, 2026
- 6-K reportMay 11, 2026
- 6-K reportMay 11, 2026
- 6-K reportMay 8, 2026
- 6-K reportMay 8, 2026
- 6-K reportMay 7, 2026
- 6-K reportMay 5, 2026
- 6-K reportMay 4, 2026
- EFFECT reportMay 4, 2026
- 6-K reportApr 27, 2026
- 6-K reportApr 23, 2026
- 6-K reportMar 31, 2026